Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Betamethasone diproprionate/calcipotriol - LEO Pharma

Drug Profile

Betamethasone diproprionate/calcipotriol - LEO Pharma

Alternative Names: Cal/BD foam - Leo Pharma; Calcipotriene/betamethasone propionate; Calcipotriol/betamethasone diproprionate; Daivobet; Daivobet 50/500 Ointment; Daivobet Gel; Dovobet; Enstilar; LEO 90105; LEO-80185; LEO-90100; LEO90100 cutaneous spray; LP-0113; Taclonex; Taclonex Scalp; Xamiol

Latest Information Update: 10 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LEO Pharma
  • Developer Kyowa Kirin; LEO Pharma
  • Class Anti-inflammatories; Antiallergics; Antipsoriatics; Cyclohexenes; Dihydroxycholecalciferols; Fluorinated steroids; Glucocorticoids; Indenes; Small molecules; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Plaque psoriasis; Psoriasis

Most Recent Events

  • 08 May 2024 Updated efficacy and adverse event data from a phase III trial in Plaque psoriasis released by LEO Pharma
  • 05 Mar 2024 LEO Pharma completes phase III trial for Plaque psoriasis in China (Topical) (NCT05919082)
  • 29 Jun 2023 LEO Pharma plans a phase III trial for Plaque psoriasis in China (Topical) (NCT05919082)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top